Onno Stolpe - Galapagos CEO
| GLPG Stock | USD 29.45 0.38 1.31% |
CEO
Mr. Onno van de Stolpe has served as Chief Executive Officer, Executive Director, Member of the Executive Committee of Galapagos NV since June 1999. He founded Galapagos in 1999 while he was Managing Director Genomics at Introgene . Prior to joining Introgene in 1998, he was Managing Director of Molecular Probes Europe. He established this European headquarters after joining Molecular Probes in the United States. Previously, he worked for the Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotech and medical device companies to locate in the Netherlands. Mr. van de Stolpe started his career as Manager Business Development at MOGEN in Leiden. He currently also serves as a member of the supervisory board of the Stichting Institute for Human Organ and Disease Model Technologies and has previously served as a member of the board of directors of DCPrime B.V since 1999.
| Age | 57 |
| Tenure | 25 years |
| Address | Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800 |
| Phone | 32 1 534 29 00 |
| Web | https://www.glpg.com |
Galapagos Management Efficiency
The company has return on total asset (ROA) of (0.0111) % which means that it has lost $0.0111 on every $100 spent on assets. This is way below average. Galapagos' management efficiency ratios could be used to measure how well Galapagos manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Galapagos' Return On Equity is most likely to increase slightly in the upcoming years. At this time, Galapagos' Total Current Assets are most likely to increase significantly in the upcoming years. The Galapagos' current Intangible Assets is estimated to increase to about 134.3 M, while Intangibles To Total Assets are projected to decrease to 0.04.Similar Executives
| Found 3 records | CEO Age | ||
| Amy MBA | Terns Pharmaceuticals | 53 | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Daniel MBA | Acumen Pharmaceuticals | 53 | |
Management Performance
| Return On Equity | -0.0015 | ||||
| Return On Asset | -0.0111 |
Galapagos NV ADR Leadership Team
Elected by the shareholders, the Galapagos' board of directors comprises two types of representatives: Galapagos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galapagos. The board's role is to monitor Galapagos' management team and ensure that shareholders' interests are well served. Galapagos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galapagos' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rajesh Parekh, Non-Executive Chairman of the Board | ||
| John Montana, Managing Argenta | ||
| Marieke Vermeersch, Head Communication | ||
| Ellen Aar, Head Development | ||
| Annelies Missotten, Executive Officer | ||
| Michele MBA, Head Commercial | ||
| Piet Wigerinck, Chief Scientific Officer | ||
| Chantal Tasset, Head Devel | ||
| Sofie Gijsel, Head Relations | ||
| Valeria Cnossen, Executive Counsel | ||
| Christine Mummery, Non-Executive Independent Director | ||
| Bart Filius, CFO | ||
| Onno Stolpe, Co-Founder, CEO, Managing Director and Executive Director | ||
| PharmD Raboisson, Head VP | ||
| Andre Hoekema, Sr. VP of Corporate Devel. | ||
| Katrine Bosley, Independent Non-Executive Director | ||
| Walid AbiSaab, Member of the Executive Committee, Chief Medical Officer | ||
| Howard Rowe, Non-Executive Independent Director | ||
| Dirk Naeyer, Head Operations | ||
| Alice Dietrich, Head Affairs | ||
| Harrold Barlingen, Non-Executive Director | ||
| Philippe Alen, Senior Development | ||
| Elizabeth Goodwin, VP Corporate Communications & Investor Relations | ||
| Mary Kerr, Non-Executive Independent Director | ||
| Thad Huston, CFO COO | ||
| MBA MBA, COO Pres | ||
| Werner Cautreels, Non-Executive Independent Director |
Galapagos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Galapagos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0015 | ||||
| Return On Asset | -0.0111 | ||||
| Profit Margin | 0.88 % | ||||
| Operating Margin | (0.34) % | ||||
| Current Valuation | (1.78 B) | ||||
| Shares Outstanding | 65.9 M | ||||
| Shares Owned By Institutions | 30.58 % | ||||
| Number Of Shares Shorted | 1.5 M | ||||
| Price To Earning | (15.60) X | ||||
| Price To Book | 0.66 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galapagos NV ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Galapagos Stock analysis
When running Galapagos' price analysis, check to measure Galapagos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galapagos is operating at the current time. Most of Galapagos' value examination focuses on studying past and present price action to predict the probability of Galapagos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galapagos' price. Additionally, you may evaluate how the addition of Galapagos to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Galapagos' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galapagos. If investors know Galapagos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galapagos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.19 | Earnings Share (0.06) | Revenue Per Share 0.182 | Quarterly Revenue Growth (0.12) | Return On Assets (0.01) |
The market value of Galapagos NV ADR is measured differently than its book value, which is the value of Galapagos that is recorded on the company's balance sheet. Investors also form their own opinion of Galapagos' value that differs from its market value or its book value, called intrinsic value, which is Galapagos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galapagos' market value can be influenced by many factors that don't directly affect Galapagos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galapagos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galapagos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galapagos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.